 Alendronate
"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
| Descriptor ID |
D019386
|
| MeSH Number(s) |
D02.705.206.100
|
| Concept/Terms |
Alendronate- Alendronate
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in Harvard Catalyst Profiles by year, and whether "Alendronate" was a major or minor topic of these publication.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Ralston SH, Binkley N, Boonen S, Kiel DP, Reginster JY, Roux C, Chen L, Rosenberg E, Santora A. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int. 2011 Jun; 88(6):485-94.
-
Eslami B, Zhou S, Van Eekeren I, LeBoff MS, Glowacki J. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif Tissue Int. 2011 Apr; 88(4):272-80.
-
Nistala H, Lee-Arteaga S, Carta L, Cook JR, Smaldone S, Siciliano G, Rifkin AN, Dietz HC, Rifkin DB, Ramirez F. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet. 2010 Dec 15; 19(24):4790-8.
-
Pozzi S, Raje N. Bisphosphonates and atypical femoral fractures. N Engl J Med. 2010 Sep 9; 363(11):1083-4; author reply 1084-5.
-
Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010 Aug 1; 28(22):3582-90.
-
Berry SD, Misra D, Hannan MT, Kiel DP. Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting. Aging Clin Exp Res. 2010 Jun; 22(3):231-7.
-
Hofstaetter JG, Wang J, Hofstaetter SG, Glimcher MJ. The effects of high-dose, long-term alendronate treatment on microarchitecture and bone mineral density of compact and trabecular bone in the proximal femur of adult male rabbits. Arch Orthop Trauma Surg. 2010 Jul; 130(7):937-44.
-
Treister NS, Friedland B, Woo SB. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May; 109(5):753-64.
-
Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr; 95(4):1838-45.
-
Kemeny-Suss N, Kasneci A, Rivas D, Afilalo J, Komarova SV, Chalifour LE, Duque G. Alendronate affects calcium dynamics in cardiomyocytes in vitro. Vascul Pharmacol. 2009 Nov-Dec; 51(5-6):350-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|